Common dysregulated pathways in obese adipose tissue and atherosclerosis

V. Moreno-Viedma1†, M. Amor1†, A. Sarabi1, M. Bilban2, G. Staffler3, M. Zeyda1,4 and T. M. Stulnig1*

Abstract

Background: The metabolic syndrome is becoming increasingly prevalent in the general population that is at simultaneous risk for both type 2 diabetes and cardiovascular disease. The critical pathogenic mechanisms underlying these diseases are obesity-driven insulin resistance and atherosclerosis, respectively. To obtain a better understanding of molecular mechanisms involved in pathogenesis of the metabolic syndrome as a basis for future treatment strategies, studies considering both inherent risks, namely metabolic and cardiovascular, are needed. Hence, the aim of this study was to identify pathways commonly dysregulated in obese adipose tissue and atherosclerotic plaques.

Methods: We carried out a gene set enrichment analysis utilizing data from two microarray experiments with obese white adipose tissue and atherosclerotic aortae as well as respective controls using a combined insulin resistance-atherosclerosis mouse model.

Results: We identified 22 dysregulated pathways common to both tissues with p values below 0.05, and selected inflammatory response and oxidative phosphorylation pathways from the Hallmark gene set to conduct a deeper evaluation at the single gene level. This analysis provided evidence of a vast overlap in gene expression alterations in obese adipose tissue and atherosclerosis with Il7r, C3ar1, Tlr1, Rgs1 and Semad4d being the highest ranked genes for the inflammatory response pathway and Maob, Bckdha, Aldh6a1, Echs1 and Cox8a for the oxidative phosphorylation pathway.

Conclusions: In conclusion, this study provides extensive evidence for common pathogenic pathways underlying obesity-driven insulin resistance and atherogenesis which could provide a basis for the development of novel strategies to simultaneously prevent type 2 diabetes and cardiovascular disease in patients with metabolic syndrome.

Keywords: Cardiovascular diseases, Diabetes mellitus, type 2, Insulin resistance, Atherosclerosis, Pathway analysis

Background

The metabolic syndrome is a worldwide public health challenge with a prevalence above 20% within adults in Western societies [1]. This disorder is based on several factors including visceral obesity, hypertension, dyslipidemia and hyperglycemia conferring a fivefold increased risk for type 2 diabetes and twofold for cardiovascular disease compared to the non-affected population [2, 3].

A chronic low-grade inflammation in response to obesity originating from the white adipose tissue has been identified as the link between obesity, insulin resistance, type 2 diabetes and cardiovascular disease [4–7]. Due to the simultaneous occurrence of insulin resistance and atherosclerosis, a considerable number of pathogenic pathways might be shared in the development of both conditions. In the past decades traditional approaches have been confined to identify changes in the expression levels of individual genes between two different conditions, however the integration and comprehension of large amounts of data remained a challenge [8–10]. Recently several methods and bioinformatic tools have been developed to perform pathways analyses out of gene expression data enabling to manage, integrate and
interpret them with a more holistic view and a biological meaning [11, 12]. Gene set enrichment analysis (GSEA) provides the possibility to compare data with different gene set databases of interest and reports group of genes associated with the same biological function or common pathways [12, 13]. Hence such analyses allow a more general picture on dysregulation compared to analyses focusing on individual genes.

Despite a number of investigations focusing on alterations leading to the development of either insulin resistance or atherosclerosis, there is no record in the literature systematically looking for dysregulated pathways common to insulin resistance and atherosclerosis in the same individual. Due to the concurring risk of type 2 diabetes and cardiovascular disease, the elucidation of dysregulated pathways in adipose tissue and atherosclerotic plaques should be based on an animal model that mirrors human disease by simultaneously developing adipose tissue inflammation/insulin resistance and atherosclerosis. Therefore, the aim of this study was the identification and analysis of common dysregulated pathways in obesity-induced adipose tissue inflammation and atherosclerotic plaque formation to elucidate interrelations in the concurrent development of type 2 diabetes and cardiovascular disease. Increasing our understanding on simultaneous dysregulation may indicate common molecular mechanisms that underlie type 2 diabetes and cardiovascular disease to facilitate novel preventive and therapeutic strategies in patients with metabolic syndrome. In this study we performed a pathway analysis focusing on individual genes.

Methods

Animals and diets

A combined insulin resistance/atherosclerosis mouse model established in our laboratory was used as described [14]. At 9 weeks of age, male LDL-receptor knockout mice (Ldlr−/−) were placed for 20 weeks either on normal chow (NC; V1126-000, Ssnif, Soest, Germany) or diabetogenic diet (DDC; D09071704, Research Diets Inc.) (Additional file 1: Table S1). Animals were sacrificed and AT and AO were collected and immediately snap frozen in liquid nitrogen. All mice were housed in a specific pathogen-free facility with a 12 h light/dark cycle. Mice had free access to food and water. The protocol fully complied with the guidelines on accommodation and care of animals formulated by the European Convention for the Protection of Vertebrate Animals Used for Experimental and Other Scientific Purposes and was approved by the local ethics committee for animal studies and the Austrian Federal Ministry for Science and Research.

Atherosclerosis quantification

En-face staining was used to determine atherosclerotic plaque formation as described [15]. Briefly, after sacrificing the mice the thorax was opened and the aorta was removed and cleaned removing all fat and connective tissue. Subsequently, the aorta was excised 2 mm above aortic root and below iliac bifurcation, opened longitudinally, pinned to silicone plates with acupuncture needles (asia-med, Suhl, Germany) and fixed overnight in 4 % paraformaldehyde, 5 % sucrose, 20 μM EDTA (pH 7.4). Atherosclerotic plaques were stained with Sudan IV for 15 min and destained with 75 % ethanol. Pictures were taken with a Sony Z-1000 camera and atherosclerotic lesion area was assessed by a person blinded to the samples by using ImageJ software.

Microarray analysis

The frozen tissue samples were homogenized in TRIzol® reagent (Invitrogen/Life Technologies, Carlsbad, CA, USA) and processed based on manufacturer’s instructions for the RNA isolation. Total RNA (1 μg) was used for GeneChip analysis, for AT preparation six individual samples were used, whereas in the case of AO each of the three individual samples were pooled in three groups due to a limited quantity of material. Terminal labeled cDNA, hybridization to genome-wide Mouse Gene 2.0 ST Gene Chips and scanning of the arrays were carried out according to the manufacturer’s indications (Affymetrix). Robust Multiarray Average (RMA) signal extraction, normalization and filtering were performed as described (http://www.bioconductor.org) [16, 17]. The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (TM. Stulnig et al. 2016) and are accessible through GEO Series accession number GSE76812 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76812).

Pathways analysis

For the GSEA analysis, output primary raw data from the AT or AO microarray experiments was set up as the expression data set in accordance with GSEA indications and uploaded to the software collectively with the
phenotype labels, chip annotations and either Biocarta, KEGG, Reactome or Hallmark gene sets downloaded from the Molecular Signatures Database (MSigDB) from the GSEA website. Subsequently the program was run with 1000 permutations and gene set as a permutation type, obtaining all dysregulated pathways, their respective normalized enrichment score (NES) and the enrichment plot for each microarray experiment. Statistical significances were set at a nominal p < 0.05 and false discovery rate q < 25 %. According to the GSEA directions, the pathways upregulated by NC were taken as pathways downregulated by DDC.

Afterwards, the leading edge analysis function was executed to determine all those genes that significantly contribute to the dysregulation of the pathway of interest, also called leading genes. GSEA software was also used for perform the leading genes heat maps, where higher expression values are represented with red and lower expression values with dark blue. All Venn diagrams were made with the free access Venn Diagram Plotter from the Pacific Northwest National Laboratory.

**Statistical analyses**

Data are given as mean ± SEM. Dietary treatment differences were estimated by unpaired two-tailed Student t test.

**Results**

**Diabetogenic diet induces obesity and atherosclerosis in Ldlr−/− mice**

Male Ldlr−/− mice were fed DDC or NC following the combined cardiometabolic mouse model previously established and characterized in detail in our lab [14]. The key parameters of this model were reevaluated for the mice in this study. We observed a significantly higher body weight at all time points (Fig. 1a) as well an elevated final AT weight (Fig. 1b) in Ldlr−/− mice fed DDC for 16 weeks compared to those on NC animals. Atherosclerotic plaque formation as analyzed by en-face staining revealed markedly enhanced atherosclerotic lesions in Ldlr−/− mice fed with DDC (Fig. 1c, d). Together these results point to the simultaneous development of considerable obesity and atherosclerosis in Ldlr−/− mice fed with DDC used in this study, reflecting published findings in this mouse model.

**GSEA revealed common dysregulated pathways in AT and AO from obese mice**

In this study, the output primary raw data from the AT or AO microarrays were uploaded into the GSEA with the aim to determine significantly dysregulated pathways in either tissue by the effect of the supplied diets (DDC or NC) and possible overlaps in terms of dysregulated pathways between both tissues. The analyses were compared with Biocarta, KEGG, Reactome or Hallmark as gene sets, obtaining upregulated pathways by DDC or NC for either AT or AO (Fig. 2). To identify common dysregulated pathways between AT and AO, we proceeded to match the upregulated or downregulated pathways for both tissues in each of the four analyses finding a considerable overlap in all the gene sets. The highest proportion of overlapping pathways was obtained for the Hallmark gene set (Fig. 2). Hence, the Hallmark gene set analysis was chosen for more comprehensive examinations, which allowed us to elucidate common pathways related to obesity induced AT inflammation and atherosclerosis. Hallmark gene set involves many well characterized biological processes combining numerous pathways. The dysregulated pathways from the GSEA with the Hallmark gene set are shown in Table 1 and were ranked by AT microarray NES, the main statistic to evaluate gene set enrichment. Several well-known as well as novel pathways potentially involved in type 2 diabetes and atherosclerosis were dysregulated in AT and AO from obese and atherosclerotic animals, respectively, compared with healthy counterparts. Upregulation of inflammatory genes with positive NES occurred in both AT and AO in obesity and atherosclerosis. With respect to a pathway downregulated in obese adipose tissue (negative NES), we selected the oxidative phosphorylation pathway due to experimental and clinical evidence linking mitochondrial alterations to type 2 diabetes and atherosclerosis.

**Single gene analysis of inflammatory response and oxidative phosphorylation pathways**

To investigate changes at the single gene level involved in the inflammatory response and oxidative phosphorylation pathways, we first proceeded with a leading edge analysis, which allowed us to identify those genes that are significantly affecting the dysregulation of each pathway, called leading genes. The leading genes are represented in the heatmaps (Figs. 4, 5) and in the pathway enrichment plots (Additional files 2, 3). The enrichment score that gives an idea about the overall regulation of the pathway is represented by the score at the peak of the enrichment plot. We carried out a leading edge analysis for the inflammatory response pathway in obese adipose tissue (Fig. 4a) and in atherosclerotic aortae (Fig. 4b) as well as for the oxidative phosphorylation pathways also in obese adipose tissue (Fig. 5a) and in atherosclerotic aortae (Fig. 5b). For the obese adipose tissue, a definite leading genes regulation profile was observed in all the samples in both analyzed pathways, denoted by the clear color patterns in the heatmaps (Figs. 4a, 5a). In contrast to the AT results, the leading gene regulation profile either in the inflammatory response or in the oxidative
phosphorylation pathways was not quite homogenous in all the AO samples (Figs. 4b, 5b). Nevertheless, the oxidative phosphorylation pathway was clearly downregulated in obese/atherosclerotic animals as shown in Table 1, heatmaps and enrichment plots.

We next tested for a possible overlap between the leading genes of each pathway in AT and AO. The percentage of matched leading genes from AT and AO in the inflammatory response pathway was 36 % (Fig. 6a), while it was even 54 % in oxidative phosphorylation (Fig. 6b). Additionally, the lists of common leading genes between both tissues for the inflammatory response pathway (Table 2) or oxidative phosphorylation pathway (Table 3) were obtained together with the corresponding rank metric score per gene which represents their importance in the dysregulation of the pathway with the uppermost listed genes being the most influential in the pathway in AT (Upregulated, Table 2; Downregulated, Table 3). For the inflammatory response pathway Il7r, C3ar1, Tlr1, Rgs1 and Semad4d were the highest ranked genes. Among the most highly ranked in the oxidative phosphorylation pathway were Maob, Bckdha, Aldh6a1, Echs1 and Cox8a. Non-overlapping genes regulated solely in AT or AO for inflammatory response and oxidative phosphorylation pathways are listed in the Additional file 1: Tables S2, S3, respectively. In addition, the common leading genes of the other pathways dysregulated in both analyzed tissues that have not been further analyzed in this study are presented in the Additional file 1: Table S4.

Fig. 1 Diabetogenic diet induces obesity and atherosclerosis in Ldlr−/− mice. Ldlr−/− mice were placed on either diabetogenic diet (DDC) or normal chow (NC) for 16 weeks: a mean body weight during dietary treatment (n = 12), b mean gonadal white adipose tissue (AT) weight after 16 weeks on dietary treatment (n = 12); c representative images of en-face Sudan IV stained aortae after 16 weeks of indicated treatments; d ath-

erosclerotic lesion quantification after 16 weeks of dietary treatment (n = 3).
Discussion

Type 2 diabetes and cardiovascular disease are common risks inherent with presence of metabolic syndrome and are triggered by insulin resistance and atherosclerosis, respectively. Several immunological and metabolic changes in serum levels from factors such as TNF-α [18], IL-6 [19], plasminogen activator inhibitor (PAI-1) [20], C-reactive protein (CRP) and fibrinogen [21], have been reported to be altered during insulin resistance and adipose tissue inflammation, both consequences of obesity, as well as atherosclerotic plaque formation during dyslipidemias [22, 23]. Even though diverse studies have been carried out to determine common variations at gene or protein levels between different metabolic tissues during obesity, the common pathways involved in the simultaneous development of adipose tissue inflammation and atherosclerosis remained elusive. Identification of common dysregulated pathways, however, could be a key in the development of both conditions and provide a chance for novel strategies to simultaneously prevent type 2 diabetes and cardiovascular disease in subjects at risk, i.e. those with metabolic syndrome [24, 25]. Pathway-based analysis is a powerful tool that allows to detect changes at a higher biological level than individual genes or molecules, complementing single gene level approaches with biological interactions, and thus contributing to a better understanding of the complexity of diseases [13]. Taking this together with the high reliability of the microarray technology nowadays [26–28], the pathways analyses based on microarray data can be considered as remarkably robust studies at the meta level. There are several publications showing single pathways to be involved in type 2 diabetes [29, 30] or atherosclerosis [31–33], such as focal adhesion [34], angiotensin II-NFκB [35], electron carrier activity, PPAR signaling and protein secretion [36]. However, in this study, we combined adipose tissue inflammation and atherosclerosis, in order to identify common dysregulated pathways in a systematic and unbiased manner, merging own and published data and applying different bioinformatic approaches.

Initially, we took advantage of a recently established combined insulin resistance/atherosclerosis inbred mouse model and analyzed microarray raw data from AT and AO with the GSEA software. Using four different gene sets, Biocarta, KEGG, Reactome and Hallmark as gene sets, we obtained considerably overlaps of dysregulated pathways in each of the four analyses. We choose Hallmark results to conduct a deeper look. However, to consider data from Biocarta, KEGG and Reactome.
analyses remains an interesting aim for further studies (Fig. 3).

Interestingly, the Hallmark analysis results included novel as well as already described common dysregulated pathways related with insulin resistance and atherosclerosis such as inflammatory response, IL6 JAK STAT3 signaling, TNFA signaling via NFKB, interferon gamma response, fatty acid metabolism, oxidative

| DPa | NESb | NOM p-Valc | FDRd | IRP# | MRPh | Name                                      |
|-----|------|------------|------|------|------|-------------------------------------------|
| AT  | AO   | AT         | AO   |      |      | E2F targets                               |
| x   | x    | 2.43       | 1.35 | <0.001 | 0.047 | 0.000 | 0.098                                     |
| x   | x    | 2.39       | 1.74 | <0.001 | 0.000 | 0.004 | G2 M checkpoint                          |
| x   | x    | 2.15       | 2.27 | <0.001 | 0.000 | 0.000 | x                                         |
| x   | x    | 2.12       | 2.33 | <0.001 | 0.000 | 0.000 | x                                         |
| x   | x    | 2.08       | 1.99 | <0.001 | 0.000 | 0.001 | IL6 JAK STAT3 signaling                   |
| x   | x    | 1.99       | 1.90 | <0.001 | 0.000 | 0.001 | Epithelial mesenchymal transition         |
| x   | x    | 1.97       | 1.97 | <0.001 | 0.000 | 0.000 | TNFA signaling via NFKB                   |
| x   | x    | 1.88       | 1.75 | <0.001 | 0.000 | 0.000 | Mitotic spindle                          |
| x   | x    | 1.86       | 2.10 | <0.001 | 0.000 | 0.000 | Complement                                |
| x   | x    | 1.86       | 2.10 | <0.001 | 0.000 | 0.000 | x                                         |
| x   | x    | 1.81       | 1.41 | 0.002  | 0.045 | 0.001 | Protein secretion                         |
| x   | x    | 1.72       | 1.89 | <0.001 | 0.000 | 0.001 | Apoptosis                                 |
| x   | x    | 1.63       | −1.34| 0.001  | 0.026 | 0.008 | MTORC1 signaling                         |
| x   | x    | 1.60       | 2.35 | 0.001  | <0.001 | 0.011 | Interferon gamma response                 |
| x   | x    | 1.58       | 1.61 | 0.021  | 0.021 | 0.013 | x                                         |
| x   | x    | 1.50       | 1.48 | 0.006  | 0.012 | 0.027 | Coagulation                               |
| x   | x    | 1.48       | 0.012| 0.030  |      |      | Unfolded protein response                 |
| x   | x    | 1.43       | 0.015| 0.047  |      |      | MYC targets V1                           |
| x   | x    | 1.41       | 0.024| 0.051  |      |      | x                                         |
| x   | x    | 1.36       | 0.027| 0.073  |      |      | IL2 STAT5 signaling                      |
| x   | x    | 1.34       | 1.68 | 0.024  | <0.001| 0.084 | FS3 pathway                              |
| x   | x    | −1.45      | −1.72| 0.016  | <0.001| 0.036 | 0.004 | x                                         |
| x   | x    | −1.56      |      | <0.001 |      | 0.000 | Peroxisome                               |
| x   | x    | −1.65      | −2.14| <0.001 | <0.001| 0.000 | 0.000 | x                                         |
| x   | x    | −1.86      | −1.46| <0.001 | 0.003 | 0.000 | 0.038 | Xenobiotic metabolism                    |
| x   | x    | −2.17      | −2.40| <0.001 | <0.001| 0.000 | 0.000 | x                                         |
| x   | x    | −2.44      | −2.15| <0.001 | <0.001| 0.000 | 0.000 | x                                         |
| x   | x    | −3.06      | −2.38| <0.001 | <0.001| 0.000 | 0.000 | x                                         |
| x   | x    | 2.08       |      | <0.001 | 0.000 | 0.000 | Interferon alpha response                |
| x   | x    | 1.72       |      | <0.001 |      | 0.005 | Heme metabolism                          |
| x   | x    | 1.63       |      | 0.001  | 0.010 |      | Apical junction                          |
| x   | x    | 1.50       |      | 0.007  | 0.031 |      | x                                         |
| x   | x    | −1.77      | <0.001|       |       | 0.002 | Spermatogenesis                          |

Commonly dysregulated pathways in AT and AO are shown in italics.

Dysregulated pathways are sorted by descending NES in AT.

- Dysregulated pathways
- Obese white adipose tissue
- Atherosclerotic aortae
- Normalized enrichment score
- Nominal p value
- False discovery rate
- Inflammation related pathways
- Metabolism related pathways
phosphorylation and adipogenesis (Table 1). This list of pathways could be of a great tool for researchers who are interested in the common mechanisms behind adipose tissue inflammation and atherosclerosis, since common genes enclosed in the pathways could be new
After evaluation of the common pathways altered in both metabolic processes, we selected the inflammatory and oxidative phosphorylation pathways as representatives of up- and down-regulated pathways, respectively, due to the importance of the involved genes in the pathogenesis of type 2 diabetes and atherosclerosis [37–41]. We could show a clear expression pattern for all genes that contribute to the dysregulation of the pathway in each tissue (Figs. 4, 5). The upregulation of the inflammatory response pathway in inflamed adipose tissue as well as in atherosclerotic aorta in the animal model used in

targets to investigate mechanism as well as possible future treatments.

Table 2 Common genes from obese adipose tissue and atherosclerotic aortae involved in the inflammatory response pathway

| Rank metric score | Gene symbol | Gene name                                      |
|-------------------|-------------|------------------------------------------------|
| AT^a              | AO^b        |                                                |
| 4.554 2.000       | Il7r        | Interleukin 7 receptor                         |
| 3.713 2.000       | C3ar1       | Complement component 3a receptor 1            |
| 3.652 0.928       | Emr1        | Adhesion G protein–coupled receptor E1         |
| 3.489 0.579       | Tlr1        | Toll-like receptor 1                           |
| 3.298 1.000       | Rgs1        | Regulator of G-protein signalling 1            |
| 3.285 0.576       | Semad4d     | Semaphorin 4D                                  |
| 3.205 0.940       | Cyyb        | Cytochrome b-245 heavy chain                   |
| 3.175 0.445       | Kcnj2       | Inward rectifier potassium channel 2          |
| 3.111 0.779       | C5ar1       | C5a anaphylatoxin chemotactic receptor 1       |
| 3.037 1.000       | Cd48        | CD48 antigen                                   |
| 2.961 1.000       | Pik3r5      | Phosphoinositide-3-kinase, regulatory subunit 5, p101 |
| 2.626 0.926       | Ptafr       | Platelet-activating factor receptor            |
| 2.422 0.894       | Ptpre       | Protein tyrosine phosphatase, receptor type, E |
| 2.364 0.716       | P2rx4       | Purinergic receptor P2X, ligand-gated ion channel, 4 |
| 2.346 2.000       | Timp1       | Tissue inhibitor of metalloproteinase 1        |
| 2.197 2.000       | Il10ra      | Interleukin 10 receptor, alpha                 |
| 1.692 0.519       | Plaur       | Plasminogen activator, urokinase receptor      |
| 1.594 0.496       | Clec5a      | C-type lectin domain family 5, member a        |
| 1.535 0.361       | Gna15       | Guanine nucleotide binding protein, alpha 15   |
| 1.452 0.922       | Cd2         | Chemokine (C–C motif) ligand 2                |
| 1.303 0.273       | Ifnar1      | Interferon (alpha and beta) receptor 1         |
| 1.129 0.957       | Ccl7        | Chemokine (C–C motif) ligand 7                |
| 1.090 1.000       | Csf3r       | Colony stimulating factor 3 receptor (granulocyte) |
| 0.921 0.460       | Il1r1       | Interleukin 1 receptor, type I                |
| 0.905 0.697       | Ccl5        | Chemokine (C–C motif) ligand 5                |
| 0.882 0.782       | Icam1       | Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor |
| 0.806 0.277       | Sltc11a2    | Solute carrier family 11, member 2            |

Dysregulated genes are sorted by descending rank metric score in AT

^a Obese gonadal white adipose tissue

^b Atherosclerotic aortae
Table 3  Common genes from obese adipose tissue and atherosclerotic aortae involved in the oxidative phosphorylation pathway

| Rank metric score | Gene symbol | Gene name |
|-------------------|-------------|-----------|
| AT\(^a\)          | AO\(^b\)    |           |
| −2.2950           | −0.4060     | Monoamine oxidase B |
| −2.0570           | −0.3260     | Branched chain keto acid dehydrogenase E1, alpha polypeptide |
| −2.0250           | −0.8910     | Aldehyde dehydrogenase 6 family, member A1 |
| −2.0020           | −0.2060     | Ech 1 Enoyl CoA hydratase, short chain, 1, mitochondrial |
| −1.7080           | −0.3710     | Cytochrome c oxidase subunit 8a |
| −1.4980           | −0.7180     | Phyh Phytanoyl-CoA hydroxylase |
| −1.4240           | −0.1680     | Cox4i1 Cytochrome c oxidase subunit IV isoform 1 |
| −1.3880           | −0.3800     | Acot2 Aconitase 2, mitochondrial |
| −1.3400           | −0.2640     | Acat1 Acetyl-CoA acetyltransferase 1 |
| −1.3350           | −0.2220     | Nduf88 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8 |
| −1.3200           | −0.1620     | Nduf1 NADH dehydrogenase (ubiquinone) flavoprotein 1 |
| −1.3060           | −0.3470     | Atp5d ATP synthase, H\(^{+}\) transporting, mitochondrial F1 complex, delta subunit |
| −1.2750           | −0.2330     | Nduf7 NADH dehydrogenase (ubiquinone) Fe–S protein 7 |
| −1.2670           | −0.4190     | Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 |
| −1.2370           | −0.2430     | Gpx4 Glutathione peroxidase 4 |
| −1.2260           | −0.4390     | Pdh1 Pyruvate dehydrogenase E1 alpha 1 |
| −1.2060           | −0.4440     | Sdhc Succinate dehydrogenase complex, subunit C, integral membrane protein |
| −1.2030           | −0.3650     | Cs Citrate synthase |
| −1.1660           | −0.3270     | Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 |
| −1.1510           | −0.2410     | Ndufa8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8 |
| −1.1450           | −0.1990     | Cox6b1 Cytochrome c oxidase subunit VIIb polypeptide 1 |
| −1.1290           | −0.3140     | Mtrp15 Mitochondrial ribosomal protein S15 |
| −1.1150           | −0.2280     | Idh3 g Isocitrate dehydrogenase 3 (NAD\(^{+}\)) gamma |
| −1.0870           | −0.1990     | Acadvl Acyl-Coenzyme A dehydrogenase, very long chain |
| −1.0820           | −0.1850     | Ndufa9 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9 |
| −1.0620           | −0.3370     | Cox6a1 Cytochrome c oxidase subunit Vla polypeptide 1 |
| −1.0570           | −0.2870     | Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 |
| −1.0470           | −0.1760     | Mfn2 Mitofusin 2 |
| −1.0230           | −0.5940     | Pdhb Pyruvate dehydrogenase (lipoamide) beta |
| −1.0140           | −0.3930     | Idh3b Isocitrate dehydrogenase 3 (NAD\(^{+}\)) beta |
| −0.9750           | −0.5050     | Atp5g3 ATP synthase, H\(^{+}\) transporting, mitochondrial F0 complex, subunit C3 (subunit 9) |
| −0.9440           | −0.1990     | Uqcrfs1 Ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1 |
| −0.9060           | −0.2240     | Mtrp34 Mitochondrial ribosomal protein L34 |
| −0.8870           | −0.2150     | Uqcrh Ubiquinol-cytochrome c reductase hinge protein |
| −0.8840           | −0.3650     | Gpelt1 GpdE–like 1, mitochondrial |
| −0.8440           | −0.2340     | Uqcr2 Ubiquinol-cytochrome c reductase core protein 2 |
| −0.8300           | −0.1600     | Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 |
| −0.8010           | −0.5270     | Ldhb Lactate dehydrogenase B |
| −0.7460           | −0.2100     | Phb2 Prohibitin 2 |
| −0.7320           | −0.2170     | Mtrp11 Mitochondrial ribosomal protein L11 |
| −0.7270           | −0.4530     | Cox6c Cytochrome c oxidase subunit Vlc |
| −0.7160           | −0.6190     | Cox5b Cytochrome c oxidase subunit Vb |
| −0.7090           | −0.1590     | Suclg1 Succinate-CoA ligase, GDP-forming, alpha subunit |
| −0.7080           | −0.2300     | Cox7b Cytochrome c oxidase subunit VIIb |
| −0.7030           | −0.1930     | Atp5j ATP synthase, H\(^{+}\) transporting, mitochondrial F0 complex, subunit F |
| −0.6970           | −0.3770     | Cox5a Cytochrome c oxidase subunit Va |
| −0.6920           | −0.2190     | Dlst Dehydrodolpoamide 5-succinyltransferase |
this study complements the recent findings showing after a long term high fat diet (16 weeks) that the homeostasis of the immune system is altered from a physiological immune response to a pathological state [42]. Moreover, the down-regulation of the oxidative phosphorylation pathway in AT supports the observations indicating decreased expression of the genes implicated in the mitochondria electron chain in visceral adipose tissue in type 2 diabetes [39]. However, our study shows the down-regulation of the oxidative phosphorylation pathway also in the atherosclerotic aorta. Additionally we also identified a considerable number of common genes between both analyzed tissues that significantly contribute to the dysregulation of the inflammatory response or the oxidative phosphorylation pathways and could be potentially involved in the pathogenesis of both type 2 diabetes and cardiovascular disease (Fig. 6; Tables 2, 3).

A large amount of studies have been performed to identify potential treatment strategies for multifactorial diseases which are caused by a collective dysregulation of many genes. Recently, identification of dysregulated pathways was proposed as possible biomarkers for such disorders [43, 44]. This study conferred a strong evidence of similarities on the pathogenesis between insulin resistance and atherosclerosis, which could support diagnostic processes and drug design in a more effective manner facilitating a more personalized medicine in patients with metabolic syndrome.

**Conclusion**

In conclusion, we describe analogies at the pathway as well as individual gene level between obese adipose tissue and atherosclerotic aortae potentially to be considered as a basis to achieve novel therapeutic approaches for the simultaneous prevention of type 2 diabetes and atherosclerotic cardiovascular disease.
References
1. Balkau B, Vennas M, Mhamdi L, Novak M, Aronnel D, Vol S, Tichet J, Eschwege E. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.R. study. Diabetes Metab. 2003;29(5):526–32.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,0

3. Kaur J. A comprehensive review on metabolic syndrome. Cardiovasc Diabetol. 2014;13:23.

4. Merino B, Zeller I, Ploner C, Frotschnig S, Ringer T, Steinacher-Nigisch A, Ritsch A, Laufer G, Huck C, Bernhard D. Ureic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis. 2011;219(2):402–8.

5. Grundy SM. Adipose tissue and metabolic syndrome: too much, too little activity. (to T.M.S.).

6. Grundy SM. Adipose tissue and metabolic syndrome: too much, too little activity. (to T.M.S.).

7. O’Rourke RW. Inflammation in obesity-related disease. Surgery. 2008;143(5):1579–98.

8. Curtis R, Oresic M, Vidal-Puig A. Pathways to the analysis of microarray data. Trends Biotechnol. 2005;23(8):329–35.

9. Kurat A, Chivers J, Kipps T, Sis B, Hillier LF, Halloran F, Wilson J. Accelerated mouse models of obesity and metabolic disorders. Trends Biotechnol. 2013;31(10):462–71.

10. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and emerging technologies. Brief Funct Genomics. 2011;10(1):49–61.

11. Sun S, Ji Y, Kersten S, Qi L. Mechanisms of inflammatory responses in adipose tissue. J Clin Invest. 2011;121(6):2111–7.

12. Messner B, Zeller I, Ploner C, Froschting S, Ringer T, Steinacher-Nigisch A, Ritsch A, Laufer G, Huck C, Bernhard D. Ureic acid causes DNA-damage, p53-mediated, mitochondria- and caspase-dependent human endothelial cell apoptosis, and accelerates atherosclerotic plaque formation in vivo. Atherosclerosis. 2011;219(2):402–8.

13. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Riddellstrale M, Laurila E, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–73.

14. Neufhoer A, Wernly B, Leitner L, Sarabi A, Sommer NG, Staffler G, Zeyda M, Stulnig TM. An accelerated mouse model for atherosclerosis and adipose tissue inflammation. Cardiovasc Diabetol. 2014;13:23.

15. Pataro S, Di Angelantonio E, Fennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.

16. Huber W, Carey VJ, Gentleman R, Anders S, Carlson M, Carvalho BS, Bravo HC, Davis S, Gatto L, Girke T, et al. Orchestrating high-throughput genomic analysis with bioconductor. Nat Methods. 2015;12(2):115–21.

17. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, Ellis B, Gautier L, Ge Y, Gentry J, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004;5(10):R80.

18. Zahorska-Markiewicz B, Janowska J, Olszanecka-Glinarowicz M, Majewski T. Serum concentration of tumor necrosis factor in obese women. J Endocrinol Invest. 1999;22:66–66.

19. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract. 2005;69(1):29–35.

20. Festa A, D’Agostino R Jr, Tracy R, Haffner SM. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51(4):1131–7.

21. Kapote S, Di Angelantonio E, Fennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. 2012;367(14):1310–20.

22. Pradhan AD, Ridker PM. Do atherosclerosis and type 2 diabetes share a common inflammatory basis? Eur Heart J. 2002;23(11):831–4.

23. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98–107.

24. Ridker PM, Luscher TF. Anti-inflammatory therapies for cardiovascular disease. Eur Heart J. 2014;35(27):1782–91.

25. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116(7):1793–801.

26. Allanach K, Mengel M, Eichecke G, St, Hidalgo LG, Mueller T, Halloran PF. Comparing microarray versus RT-PCR assessment of renal allograft biopsies: similar performance despite different dynamic ranges. Am J Transplant. 2008;8(5):1006–15.

27. Wumbach E, Yuen T, Ebersole BJ, Sealoff SC. Gonadotropin-releasing hormone receptor-coupled gene network organization. J Biol Chem. 2002;276(50):46567–76.

28. Etienne W, Meyer MH, Peppers J, Meyer RA. Comparison of mRNA gene expression by RT-PCR and DNA microarray. Biotechniques. 2004;36(4):618–20.

29. Sato M, Dehvari N, Sandstrom AL, Olsen MJ, Czakos RI, Summers RJ, Hutchison DS, Bengtsson T. Improving type 2 diabetes through a distinct adrenergic signaling pathway involving mTORC2 that mediates glucose uptake in skeletal muscle. Diabetes. 2014;63(12):4115–29.

30. Munasinghe PE, Riu F, Dixit P, Edamatsu M, Saxena P, Hamer NS, Galvin IF, Bunton RW, Lequeux S, Jones G, et al. Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway. Int J Cardiol. 2015;201(3):102–12.

31. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, Kuchinsky A, Vailaya YZ, et al. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK/P3K/Akt/eNOS pathway. Vascul Pharmacol. 2015;72:141–52.

32. Eschwege E. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.R. study. Diabetes Metab. 2003;29(5):526–32.

33. Xing SS, Yang XY, Zheng T, Li WJ, Wu D, Chi JY, Bian F, Bai XL, Zhang YM, et al. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK/P3K/Akt/eNOS pathway. Vascul Pharmacol. 2015;72:141–52.

34. Zhang L, Uy E, Fu F, Dixit P, Edamatsu M, Saxena P, Hamer NS, Galvin IF, Bunton RW, Lequeux S, Jones G, et al. Type-2 diabetes increases autophagy in the human heart through promotion of Beclin-1 mediated pathway. Int J Cardiol. 2015;201(3):102–12.

35. King JY, Ferrara R, Tabibiazar R, Spin JM, Chen MM, Kuchinsky A, Vailaya YZ, et al. Salidroside improves endothelial function and alleviates atherosclerosis by activating a mitochondria-related AMPK/P3K/Akt/eNOS pathway. Vascul Pharmacol. 2015;72:141–52.

36. Shim U, Kim HN, Sung YA, Kim HL. Pathway analysis of metabolic syndrome using a genome-wide association study of Korea Associated Resource (KARE) cohorts. Genom Inform. 2014;12(4):195–202.

37. O’Rourke RW. Inflammation, obesity, and the promise of immunotherapy for metabolic disease. Sunt Obes Relat Dis. 2013;9(5):609–16.

Acknowledgements
Not applicable for this section.

Competing interests
The authors declare that they have no competing interests.

Availability of data and material
The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (TM. Stulnig et al., 2016) and are accessible through GEO Series accession number GSE76812 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE76812).

Funding
This work was supported by the Federal Ministry of Economy, Family and Youth and the National Foundation for Research, Technology and Development. (to T.M.S.).

Received: 2 July 2016   Accepted: 17 August 2016
38. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol. 2009;6(6):399–409.
39. Dahlman I, Forsgren M, Sjogren A, Nordstrom EA, Kaaman M, Naslund E, Arner P. Downregulation of electron transport chain genes in visceral adipose tissue in type 2 diabetes independent of obesity and possibly involving tumor necrosis factor-alpha. Diabetes. 2006;55(6):1792–9.
40. Rochette L, Zeller M, Cottin Y, Vergely C. Diabetes, oxidative stress and therapeutic strategies. Biochim Biophys Acta. 2014;1840(9):2709–29.
41. Kondo T, Hirose M, Kageyama K. Roles of oxidative stress and redox regulation in atherosclerosis. J Atheroscler Thromb. 2009;16(5):532–8.
42. Kim J, Kwon EY, Park S, Kim JR, Choi SW, Choi MS, Kim SJ. Integrative systems analysis of diet-induced obesity identified a critical transition in the transcriptomes of the murine liver and epididymal white adipose tissue. Int J Obes (Lond). 2015.
43. Liu Q, Liu ZP, Hao JK, Chen L, Zhao XM. Identifying dysregulated pathways in cancers from pathway interaction networks. BMC Bioinformatics. 2012;13:126.
44. Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. BMC Med Genom. 2013;6(Suppl 1):S17.